What one share of Glaukos holds
Glaukos is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal disease.
Glaukos’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $10.58 |
|---|---|
| Profit | −$3.25 |
| Capex (buildings and equipment) | $0.19 |
| Free cash flow | −$0.21 |
| Cash and investments | $1.95 |
| Book value | $11.60 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2013 | $10.29 | −$6.21 | $0.42 | −$6.95 | — | −$73.20 |
| 2014 | $19.87 | −$5.29 | $0.38 | −$3.48 | — | −$61.96 |
| 2015 | $4.10 | −$2.13 | $0.05 | −$0.18 | — | $2.96 |
| 2016 | $3.14 | $0.12 | $0.17 | $0.17 | — | $3.46 |
| 2017 | $4.63 | −$0.00 | $0.18 | $0.58 | — | $3.99 |
| 2018 | $5.13 | −$0.37 | $0.29 | $0.24 | — | $4.82 |
| 2019 | $5.76 | $0.37 | $0.11 | −$0.12 | — | $15.48 |
| 2020 | $5.06 | −$2.70 | $0.16 | −$0.67 | — | $14.75 |
| 2021 | $6.33 | −$1.07 | $1.03 | −$0.50 | — | $12.50 |
| 2022 | $5.96 | −$2.09 | $0.64 | −$1.34 | — | $11.10 |
| 2023 | $6.50 | −$2.78 | $0.42 | −$1.61 | — | $9.40 |
| 2024 | $7.27 | −$2.77 | $0.12 | −$1.28 | — | $13.59 |
| 2025 | $8.87 | −$3.28 | $0.13 | −$0.39 | — | $11.41 |
Common questions about Glaukos
How much does one share of Glaukos earn?
Over the last 12 months, Glaukos lost $3.25 for each share on $10.58 of sales.
Does Glaukos pay a dividend?
Glaukos didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Glaukos’s book value per share?
Glaukos’s book value is $11.60 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Glaukos have?
Each share of Glaukos has $1.95 of cash and investments, as of June 30, 2026.
What is Glaukos’s free cash flow per share?
−$0.21 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Glaukos bought back shares?
Glaukos’s share count rose about 2709% from 2013 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.